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Machine-assisted treatment selection commonly follows one of two paradigms: a fully personalized paradigm which ignores any possible clustering of patients; or a sub-grouping paradigm which ignores personal differences within the identified groups. While both
paradigms have shown promising results, each of them suffers from important limitations. In
this article, we propose a novel deep learning-based treatment selection approach that is
shown to strike a balance between the two paradigms using latent-space prototyping. Our
approach is specifically tailored for domains in which effective prototypes and sub-groups of
patients are assumed to exist, but groupings relevant to the training objective are not
observable in the non-latent space. In an extensive evaluation, using both synthetic and
Major Depressive Disorder (MDD) real-world clinical data describing 4754 MDD patients
from clinical trials for depression treatment, we show that our approach favorably compares
with state-of-the-art approaches. Specifically, the model produced an 8% absolute and 23%
relative improvement over random treatment allocation. This is potentially clinically significant, given the large number of patients with MDD. Therefore, the model can bring about a
much desired leap forward in the way depression is treated today.

1 Introduction
Precision Medicine (often referred to as Personalised Medicine, or PM for short) seeks to customize healthcare, with medical diagnosis, prognosis, treatment and other practices being tailored to the individual patient. This is juxtaposed with the traditional “one-drug-fits-all”
model [1]. At the heart of much of PM research and practice stands the challenge of effective
personalization, such as selecting an optimal treatment for each individual patient. The basic
premise of PM is that patients may vary in their responses to different courses of treatments
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and, as such, may benefit more from different courses of treatment. Recently, this has been
increasingly achieved with the use of machine learning models.
Within the PM realm, machine-assisted treatment selection approaches can be largely classified into one of two paradigms. The first is the Fully personalized paradigm, where historical
data is used to identify the relationships between patients’ characteristics, treatments, and
medical outcomes in order to determine the optimal course of treatment of new patients.
Using this paradigm, a model is commonly trained to approximate the individual treatment
effects of the available treatments and an optimal treatment for each patient is derived from
this model [2, 3]; The second is the Sub-grouping paradigm, where groups of “similar” patients
are identified and then associated with an optimal treatment at the group level. Using this paradigm, some clustering algorithm is used in order to identify the clusters and then each cluster
is associated with an optimal treatment [4, 5]. Sub-grouping is often referred to as prototyping
since each group of patients is commonly represented by one or more (real or virtual) “prototypical patients” which are in turn associated with an optimal treatment.
Algorithms from both treatment selection paradigms have demonstrated significant benefits across a wide range of medical applications. However, in some medical settings, both paradigms suffer from important limitations: For example, the fully personalized paradigm is
commonly focused on minimizing the prediction error over the individual treatment effects
[2, 4]. However, in practice, one is commonly more interested in identifying the “best” course
(s) of treatment. These two objectives do not necessarily coincide when the probability estimations are inherently inaccurate. Specifically, we are generally more interested in the induced
ranking over the possible treatments rather than the accuracy of the probability estimations
themselves, as the objective of treatment selection is to choose the best possible treatment from
a given set (i.e., the set of possible treatments). This concern is mitigated in some domains by
adopting a sub-grouping paradigm (e.g., [4]). Introducing subgroups makes it easier to identify which patient groups may benefit the most from different treatments. However, the subgroup paradigm introduces new shortcomings: first, defining “good” sub-grouping criteria is
challenging, especially when the pathophysiology of the disease and their relation to treatment
outcomes are unknown, as is the case in many psychiatric disorders [6]. Second, group-level
treatment selection naturally translates into some loss in accuracy when the groups are not
entirely cohesive (e.g., [7]).
In this article, we propose a novel deep learning-based approach that strikes a balance
between the two treatment selection paradigms by simultaneously identifying prototypes (subgroups) of patients as well as approximating outcome prediction in a personalized manner.
More specifically, our approach aims at finding “actionable” prototypes, meaning that they differ not only in their characteristics but, importantly, in their expected responses to the available courses of treatment. Our approach uses a novel deep-learning architecture and a
multifaceted loss function which balances between the accuracy of the prediction on the individual level and the cohesiveness of the identified prototypes in terms of predicted treatment
outcomes. Importantly, the model outputs not only group membership for a given patient, but
also personalized probabilities of treatment success for each possible treatment.
Our approach performs the prototyping identification in the latent space and, as such, it is
specifically suited for domains where a useful sub-grouping of patients is assumed to exist, but
is not observable in the non-latent space. Note that in some medical domains this assumption
may prove irrelevant as patients can be divided into cohesive sub-groups in terms of treatment
responses by observed features alone. For example, the optimal course of treatment for leukemia (and several other forms of cancer) is commonly determined by age group and other
known factors [8]. Nonetheless, in several other medical domains such as psychiatry, such
sub-grouping in the non-latent space is found to be only weakly connected with treatment
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response (see [9, 10] for a discussion). As such, sub-grouping in observable space may not be
optimal in mental health.

1.1 Treating major depressive disorder
For evaluating our proposed approach, we focus on the personalization of treatment for Major
Depressive Disorder (MDD). MDD is highly prevalent in the general population and is associated with grave consequences, including excessive mortality, disability and secondary morbidity. According to the World Health Organization (WHO), more than 300 million people were
affected by depression worldwide in 2017 [11]. In the United States, MDD was a leading cause
of disability in all ages in year 2018, substantially more than most other physical and mental
conditions [12]. Consequently, the economic burden of MDD on society is very high [12, 13].
MDD is diagnosed based on a heterogeneous group of symptoms, and two patients with
depression can have very different clinical phenomenology. The DSM-5 criteria for depression
include loss of interest or pleasure in usual activities, depressed mood, increased or decreased
appetite or weight, increased or decreased psychomotor activity, increased or decreased sleep,
fatigue, poor concentration, feelings of guilt or worthlessness, and suicidality; a patient must
have at least five of these symptoms and at least one of these must be depressed mood or
reduced interest or pleasure [14]. The precise pathophysiology of MDD has yet to be fully elucidated [15].
Antidepressants are the most common treatment for MDD and are among the most prescribed medications [16]. While they have demonstrated effectiveness, MDD patients vary significantly in their response to the various treatments. The current status quo for MDD
treatment is an educated trial-and-error approach in which patients typically undergo several
rounds of different antidepressants [17]. In clinical practice, a single treatment course typically
lasts six months or more and roughly one third of patients do not respond to treatment following an adequate trial. This means that they can be forced to go through several unsuccessful
rounds of drug treatments, with this effort at times extending over several years [18]. This process has severe psychological, economic and social consequences for both patients and their
families [19, 20]. It is commonly assumed that MDD patients can be categorized into useful
sub-groups on the basis of presenting symptoms that may be associated with differential treatment response (e.g., [4, 21–23]). Unfortunately, commonly used clinical sub-groups of depression that are defined in the non-latent space (i.e., atypical, melancholic or anxious prototypes)
have failed to predict any significant difference among currently available antidepressant medications [9].
This need for improved treatment selection in depression, combined with the possibility
that useful sub-groups for treatment selection may exist in the latent space, make MDD an
excellent candidate disorder to test our approach. To do so, we will use both synthetic data and
clinical data. Our clinical dataset combines data from several clinical trials, and describes 4754
MDD patients who were treated as part of clinical trials of antidepressant treatment. Each
patient in these datasets is described by sociodemographic information and clinical symptomatology at baseline, the treatment they received, and the outcome of the treatment after 12
weeks. Below, we describe the datasets in further detail (Subsection 5.4.1 and Appendix B).
The synthetic data, described below, has similar characteristics to the clinical dataset. Using
both of these datasets, we demonstrate our approach’s added value compared to state-of-theart methods aimed at improving treatment selection for MDD. Given that the current standard
of treatment for many psychiatric disorders, including MDD, is an educated “trial-and-error”
approach [24], our approach could help bring about a much desired leap forward in treatment
effectiveness in terms of increased remission rates and reduced length of the process of finding
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optimal treatments at the individual patient level. In turn, this can translate to a reduced social
and economical burden from MDD in the population level.

2 Related work in machine-assisted treatment selection
Automated treatment selection is an evolving field which has recently garnered increased
interest from researchers [2] and by the media [25]. As discussed above, AI-based treatment
selection in healthcare is commonly addressed through two different computational paradigms: the fully personalized and sub-grouping approaches. Both approaches have had success.
For example, for eradicating brain tumors, a fully-personalized approach has been shown to
effectively maximize the expected clinical benefits while minimizing side effects [26]. With
respect to subgrouping approaches, in [27], the authors suggested clusters based on nonadherence for psychosis treatment. More recently, researchers have shown that these clusters
demonstrate significant differences in terms of re-hospitalisation rates and maintenance of the
original medication [28]. However, as described above, both approaches have significant limitations. Fully personalized approaches can focus too much on maximizing accuracy when the
desired output is differential treatment benefit and they do not utilize potentially useful information related to patient subgroups; and, by design, the sub-grouping paradigm does not
explicitly capture the possibly complex links between individual patients’ features, treatment
and possible outcomes, and it does not provide explicit predictions for expected outcome on
an individual level. In addition, in many cases, the sub-groups can overlap such that a single
patient may be associated with more than one cluster. Therefore, a simple mapping from clusters to treatments may not suffice.
In order to mitigate these limitations we propose a novel model, which we will call Differential Prototypes Neural Network (DPNN for short). DPNN is proposed as a middle-ground
solution between the two existing paradigms discussed above. Similar to the fully-personalized
paradigm, during training the DPNN considers the outcome prediction accuracy on an individual level. At the same time, it takes inspiration from the sub-grouping paradigm by performing prototyping which directly feeds into the individual level prediction. Unique to our
approach is simultaneous optimization of both the sub-groupings and the individual
predictions.
Unlike traditional unsupervised clustering methods, the prototypes are constantly tuned
during the training process in order to guarantee that the prototypes will approximate an optimal treatment selection policy. To the best of our knowledge, this is the first work that applies
such an approach in the field of PM. We will now discuss similar approaches in previous
studies.
A Similar approache to DPNN is the work described by Ross et al. [7], that addresses effective pediatric asthma treatment. This approach also combines both the fully personalized and
sub-grouping paradigms. However, unlike DPNN, which simultaneously considers subgrouping and personalized outcome prediction accuracy, Ross et al. perform these tasks
sequentially. Specifically, their approach divides the patients into clusters and later assigns different outcome prediction models for each possible sub-group. The process is then continued
until there are no prediction performance improvements that can lead to further changes in
clusters. Another difference between the approaches is that DPNN is also suited for treating
patients who can be associated with more than one cluster, as is the case in many medical settings including depression treatment [9].
Our approach draws inspiration from the models proposed in [29, 30] for promoting
interpretability in classification tasks. In these works, neural network architectures are utilized
for partitioning samples into sub-groups in various classification tasks. Unlike in our
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approach, these prototypes have not been linked, explicitly or implicitly, to optimal interventions or treatments. Our task, is to improve decision-making, which requires the linkage of
subgroups to outcomes (given treatments). As such, our task leads to fundamental differences
in network architecture from previous work and the development of a suitable loss function as
discussed in Section 4.1.
In order to better situate our proposed approach in the field and evaluate its potential benefits over the standard “fully personalized” and “sub-grouping” paradigms, we adopt a few key
representatives of each approach for comparison and discuss them next. These representatives
are also used in our experimental evaluation in Section 5.
Starting with the fully personalized paradigm, we use three representatives: 1) A state-ofthe-art method for estimating Individualized Treatment Effects (ITE) called CFRnet [31]; 2) A
state-of-the-art deep-learning model explicitly designed for depression treatment selection
called Vulcan [32]; and 3) A classic Case Based Reasoning (CBR) approach [33]. We discuss
these representatives next and contrast them with our approach.
Methods for estimating ITE, and specifically CFRNet, focus on leveraging available clinical
data for predicting outcomes of treatments [34, 35]. This line of research mainly addresses the
lack of counterfactual data in clinical results, meaning that the available data consists of only
the outcome of a single administered treatment for each patient. Recent advances in this line
of work have investigated methods that focus on balancing the distributions of control and
treated groups (e.g., [36]). It is important to note that our task is slightly different for two main
reasons: 1) We assume minimal selection bias in the data, given that the data was collected
from clinical trials in which the patients were assigned randomly to the different treatment
conditions or were all assigned to the same treatment for each patient; and 2) Our main objective is not (solely) to accurately predict or quantify the effects of possible treatments, but rather
to find the best treatment(s). In other words, the correct ranking of the treatments is the main
objective, as opposed to solely maximizing prediction accuracy. The CFRnet method [31], is a
prime example of this approach which uses a deep learning framework for counterfactual
regression, that simultaneously fits a balanced representation of the data and an hypothesis for
the outcome of counterfactuals.
Vulcan is a deep-learning based treatment selection component of the Aifred system [37]
and is considered to be the state-of-the-art representative of the fully personalized paradigm
for MDD treatment selection. Vulcan is explicitly designed for depression treatment selection
and was recently evaluated on a subset of the MDD data set used in this study as well (see Section 5.4.1). This evaluation revealed that it is superior to other machine learning based
approaches such as random forests [32]. Similar to the CFRNet method, Vulcan uses a neural
network based model that is fed with the features of a patient and a specific treatment and outputs the remission probability associated with that treatment.
Case-based recommender systems (CBR) is a private case of the Recommender Systems
[38] approach which seeks to select the best item(s) from a set of possible items for a given
user, according to his or her estimated preferences. In analogy to our task, a patient can be
viewed as a “user”, the treatments can be viewed as “items” and the “preferences” in our context would be the suitability of the treatment to the patient. However, most common
approaches for RS (e.g. collaborative filtering, content based) require many interactions
between users and items [39], while in clinical data each patient is often administered only a
single treatment and experiences only a single outcome. Nevertheless, several researchers have
investigated RS that utilize the CBR approach for treatment selection (e.g. [33]) which relies
on the idea of detecting similarities between patients. These have also been applied for mental
health treatment selection [40].
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For the subgrouping paradigm, we use two representatives: 1) A standard K-means clustering algorithm [41]; and 2) A state-of-the-art depression sub-grouping approach based on
latent profile analysis [4]. We discuss these representatives next and contrast them with our
approach.
The most straight-forward method to perform sub-grouping is to implement one of the
classic clustering algorithms available today [42]. In this work, we chose the popular K-Means
algorithm in order to cluster the patients. We represented each patient with the relation to the
K-Means clusters’ centroids and fed each patient to a separately trained fully-connected classification neural network in order to predict the outcome of the treatment. We term this method
as KMNN.
A more advanced implementation of the subgrouping paradigm is introduced by Saunders
et al. [4, 23], who have shown that using Latent Profile Analysis (LPA) [43], MDD patients can
be divided into eight sub-groups that differ significantly in their reaction to treatments and
specifically in the most effective treatment. This method, which we will refer to as LPAD
(Latent Profile Analysis for Depression treatment), is considered the state-of-the-art representative of the sub-grouping paradigm.

3 Problem definition
Let us define our treatment selection problem setting more formally.
We are given a data set of N samples D = {(x1, t1, y1). . ., (xN, tN, yN)}, where xi describes a
patient sampled from a given distribution χ and represented as a d dimensional feature vector
xi 2 Rd, ti 2 T indicates the treatment received by patient xi from a finite set of k > 1 treatment
options, and yi 2 Y indicates the observed outcome of the treatment. Importantly, we assume
D resulted from an unbiased treatment selection, such as a controlled clinical trail. Namely, the
assignment of each patient xi to ti was independent of xi. Formally, for any t 2 T, p(t|xi) = p(t).
We assume that Y is binary and consists of only a desired outcome and a non-desired outcome. Adopting the terminology of our application domain (i.e., MDD treatment), we refer to
the desired outcome as remission, denoted as r, and a non-desired outcome as non-remission,
denoted r�. It is important to note that our formulation and approach can be readily adapted to
any outcome space of choice and the above restriction is for presentation and evaluation purposes only.
Assuming there are k potential treatments, for a given patient xi, there are k corresponding
potential binary outcomes: yið0Þ ; yið1Þ ; . . . ; yiðk 1Þ , where yiðjÞ 2 f0; 1g. However, our data consists
of only a single observed outcome for xi who received ti, namely yðti i Þ . In other words, D does
not include the counterfactuals—namely, the outcomes of non-received treatments t 6¼ ti.
The optimal treatment selection policy, π� , assigns ti� for each patient xi such that it maximizes the desired outcome probability (i.e., remission). Formally, for a patient x,
p� ðxÞ ¼ argmax Prðrjx; tÞ

ð1Þ

t2T

where Pr(r|x, t) is the probability of remission for patient x given treatment t. Naturally, the
true probability is unknown.

4 Approach
Since Pr(r|x, t) is unknown, deriving an optimal treatment selection policy as defined in Section 3 is very complex. Similar to other treatment selection techniques proposed in the literature (see Section 2), we tackle this challenge by approximating Pr(r|x, t) such that
b
Prðrjx;
tÞ � Prðrjx; tÞ. However, our true objective is to “approximate” the optimal policy π�
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by deriving a treatment selection policy as follows:
b
tÞ
pðxÞ ¼ argmax Prðrjx;
t2T

ð2Þ

By approximating the optimal policy we mean that we seek to minimize the following loss
function:
LossðpÞ ¼ E ½Prðrjx; pðxÞÞ
x�w

Prðrjx; p� ðxÞÞ�

ð3Þ

However Pr(r|x, t) is unknown. As such, any approximation thereof need not necessarily
minimize the above loss. To overcome this hurdle, we propose to approximate Pr(r|x, t) in an
unorthodox way such that it would potentially prove more useful for minimizing the above
loss indirectly compared to standard approximations to Pr(r|x, t). Our method leverages the
assumption that patients may be divided into sub-groups which vary significantly in their reactions to treatments as discussed in Section 2. In this work, we implement our approximation
approach with a neural network based architecture, that: 1) identifies prototypes of patients;
and 2) predicts the remission probability for each patient-treatment pair based on the their
resemblances to identified prototypes. We discuss our proposed neural architecture and loss
functions in following subsections.

4.1 Model architecture
Our proposed neural network architecture consists of the following three main components
(which will be explained thereafter):
1. A symmetrical autoencoder, including an encoder—e: Rm ! Rq, and a decoder—d: Rq !
Rm.
2. A prototype layer, g.
3. A classification network h: Rq ! RK.
The architecture uses an autoencoder in order to produce features in the latent-space, Rq.
We denote the dimension of the original data as m and the dimension of encoded data as q.
The encoded data is used for both finding prototypes and to calculate the outcome prediction
for each patient separately. Specifically, for each patient xi, the network first encodes the m features of xi into an encoded representation denoted as e(xi). e(xi) is used in two ways: 1) It is
used together with the decoder d in order to complete the auto-encoding process and; 2) It is
fed into the prototype layer.
The prototype layer g consists of ℓ randomly initiated prototypes P = {p1, p2, . . .pℓ} each of
q dimensions. In this layer, the architecture calculates the distance between the encoded sample e(xi) and each of the prototype vectors using some distance measure. These distances,
denoted as di ¼ fdi1 ; di2 . . . ; di‘ g, have practically reduced each patient’s representation to an ℓdimensional encoding. Finally, the resulting encoding is fed together with the treatment representation (t 2 T) into a standard classification network, h.
The classification network h is a standard fully connected neural network, used for obtaining a probability distribution over the possible outcomes. During the training process, after
obtaining these probabilities, the network calculates the loss, as described below (Section 4.2),
and then back-propagates the loss value in order to tune all the components of the network,
including the prototypes. By doing so, the prototypes are tuned in order capture differences in
the treatment effect. A visualization of the entire architecture is given in Fig 1.
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Fig 1. Visualisation of the DPNN architecture.
https://doi.org/10.1371/journal.pone.0258400.g001

Note that the prototype vectors are randomly initialized and their values are tuned during
the training process with an appropriate loss functions which will be discussed next. The number of prototypes, ℓ, is predefined prior to the training process similar to other standard clustering-based approaches [41].

4.2 Objectives and loss functions
Recall that our main objective is to determine the most appropriate treatment(s) for each
patient. Our proposed approach seeks to accomplish that by approximating the probability
distribution of each patient-treatment pair in a way which will indirectly pursue this main goal.
As discussed before, we propose to accomplish this by leveraging the assumption that patients
may be divided into “actionable” subgroups which differ in their responses to different
treatments.
With the above motivation in mind, in addition to the standard accuracy objective, we
incorporate an additional objective which is to increase the discordance between the prototypes in respect to their expected outcomes across the possible treatments. Thus, our approach
could potentially reveal prototypes that will prove more useful for treatment selection.
These two objectives are optimized using a complex loss function that consists of the following three components:
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1. L1: The accuracy loss evaluates the binary cross-entropy loss in predicting the outcome for
the training set. Formally, for a training set D,
L1 ðh � g � e; DÞ ¼

jDj
X
1½yi ¼r� logðh � g � eðxi ÞÞ þ 1½yi ¼�r � logð1

h � g � eðxi ÞÞ

ð4Þ

i¼1

where h � g � e(xi) is the output of the network for xi and 1½yi ¼r� ð1½yi ¼�r� Þ is an indicator function for the event that the outcome of sample xi is r (r�).
2. L2: The auto-encoder loss which measures the Euclidean distance between the original samples and the decoded samples as obtained through e and d. L2 is defined as
jDj
X

L2 ðd � e; DÞ ¼

k xi

d � eðxi Þ k

ð5Þ

i¼1

By minimizing this loss the model ensures that the encoded data contains meaningful latent
features, meaning features that are rich enough to reconstruct the encoded sample as close
as possible to the original.
3. L3: Prototype variance loss. This novel component measures the variance in the expected
treatments outcomes across all prototypes. L3 is calculated as follows: Each of the ℓ encoded
prototypes is matched with each of the k possible treatments, and fed through the classification network. As a result, our network produces a matrix, denoted YP, of size ℓ × k, where
each cell contains the prediction for one possible combination of prototype and treatment.
We will denote the remission probability of prototype i with treatment κ as yki . L3 is defined
as follows:
L3 ¼

ððaÞintravar ðYP Þ þ ð1

aÞintervar ðYP ÞÞ

ð6Þ

where intravar quantifies the variance in predictions within the prototypes (across the possible treatments), intervar quantifies the variance in prediction between the different prototypes, and α 2 (0, 1) is a hyper-parameter that balances between the two types of variance.
Formally,
02 1
31
X
y1 . . . y1k
2
ðy1k m‘ Þ
‘
B6
7C X
7C
B6
k2T
intravar B6
...
ð7Þ
7C ¼
@4
5A
l
l¼1
y‘1

...

y‘k

where μℓ is the mean probability of remission for prototype l across all treatments.
Similarly,
02 1
31
‘
X
y1 . . . y1k
2
ðykl mk Þ
B6
7C X
B6
7C
l¼1
intervar B6
...
7C ¼
@4
5A k2T
‘
y‘1

...

ð8Þ

yk‘

where μκ is the mean prediction of remission for treatment k across all prototypes.
Notice that the summation of the variance terms is negated in L3 since we are interested in
increasing the variance combination.
Below we present the motivation for this type of loss and illustrate the difference between
both types of variance.
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Table 1. High variance across prototypes.
Treatment T
1
Prototype

T2

T3

P1

0.3

0.25

0.7

P2

0.35

0.2

0.65

P3

0.8

0.02

0.03

https://doi.org/10.1371/journal.pone.0258400.t001

In order to motivate and clearly illustrate L3, we provide two examples. Say our network is
configured to find three prototypes (ℓ = 3), and the dataset includes three possible treatments
(k = 3). In order to calculate L3, our network will first produce 9 different remission probabilities: 3 for each of the 3 prototypes. Now, say that the network produced the probabilities presented in Table 1.
We can observe that prototypes P1 and P2 are expected to react similarly to the possible
treatments, while they both differ significantly from P3. As our goal is to find meaningful prototypes with respect to the treatment outcome, we would like to improve the selection of prototypes by increasing the difference between P1 and P2 while keeping the clear difference
between them and P3. We obtain this goal by increasing the variance across the prototype
dimension: for each treatment, we measure the variance across all prototypes and calculate the
summation of all variances, as defined in Eq 8.
Now say the probabilities for remission were as given in Table 2.
In this example, the prototypes are clearly differentiated with respect to remission rates, but
the differences within each prototype across different treatments are minimal. These prototypes are associated with overall chances of remission. As such, they are not particularly helpful
for improving treatment selection. Therefore, we would like to make sure that the differences
between the treatments expected outcomes, within each prototype, would become more significant. Therefore, we would like to increase the variance in the expected outcomes for treatment
within each prototype. We denote this type variance as intravar as defined in Eq 7.
As can be seen from the above two examples, both types of variance are essential, yet they
are partially conflicting. The more the variance across the prototypes is increased, the more
chances are that the differences within prototypes decrease, since high variance between prototypes naturally leaves less space for variance within the prototypes and vice-versa. Therefore,
these variance components are combined through a weighted summation that allows for a customised configuration between these loss components. This controls the prototypes’ training
with the objective being that they are sufficiently spread out across the latent space so as to
potentially capture the nuances and characteristics of the patient population. A visualization of
the computation of L3 is presented in Fig 2.
We linearly combine the three loss components as:
L ¼ L1 þ l1 L2 þ l2 L3

ð9Þ

where λ1 and λ2 are hyper-parameters that balance between the different objectives of the
network.
Table 2. Low variance within prototypes.
Treatment T
1
Prototype

T2

T3

P1

0.81

0.8

0.83

P2

0.45

0.44

0.47

P3

0.19

0.2

0.18

https://doi.org/10.1371/journal.pone.0258400.t002
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Fig 2. Visualisation of L3’s computation.
https://doi.org/10.1371/journal.pone.0258400.g002

All of the components described above (the autoencoder, prototypes and classification layers) are trained simultaneously, meaning that after every single feed-forward, the combined
loss is back propagated and tunes all the components accordingly.

5 Evaluation
In order to evaluate our approach, we performed two experiments: First, we used synthetic
data which was created to follow our two central assumptions: 1) Patients can be divided into
sub-groups that differ in their reactions to different treatments; and 2) These sub-groups are
defined in the latent space. This experiment, which we will refer to as Experiment 1, is used for
demonstrating the potential benefits of our approach when our assumptions are fully met and
counterfactual data exists for evaluation purposes. Second, we use an extensive secondary realworld clinical dataset for MDD treatment selection that combines three major clinical trials
(N = 4, 754). In this experiment, which we will refer to as Experiment 2, we demonstrate the
potential benefits of our approach in a real-world, high stakes medical domain in which no
counterfactual data exists and our assumptions cannot be definitively confirmed.
In order to properly compare the proposed DPNN approach to the five benchmark
approaches discussed in Section 2, several technical amendments were needed. Next, we discuss this slight modifications followed by the results of the two experiments described above.

5.1 Benchmarks
We compared our DPNN approach to five representative methods discussed in Section 2:
1. CFRnet [31]: a neural network-based model that builds a balanced representation of the
data, in order to overcome possible bias between treatment groups, and predicts the outcome of possible counterfactuals. CFRnet was originally designed for data including two
groups of treatments and therefore we adjusted the original framework to fit multiple treatment groups, as we describe in Appendix E. CFRnet was recently evalauted in other similar
healthcare domains [31, 44].
2. Vulcan: a state-of-the-art treatment selection method specifically tailored for MDD [32].
The original code used in [37] was provided by the authors, some of which co-author this
article as well. The code was used “as-is” without further modification.
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3. CBR: the prediction of each treatment t is estimated by the k nearest neighbors (KNN) in
the dataset who received treatment t. The similarity distance is based on popular cosine
similarity measure and the prediction is calculated as the weighted sum of the neighbors’
outcomes weighted by distance.
4. KMNN: The algorithm works in two phases, first a standard K-Means algorithm is executed
to identify clusters of patients based on their observable features, regardless of treatments
and outcomes. Then, for a given patient, distances are calculated with respect to the centroids of the identified clusters which are then fed to the separately trained fully-connected
classification network in order to predict the outcome of the treatment.
5. LPAD: the state-of-the-art method for MDD treatment selection using sub-grouping [4].
As in DPNN, the clustering is performed in the latent-space. Note that, unlike DPNN,
LPAD does not explicitly predict the remission probability but rather focuses on determining optimal treatment. Therefore, a few technical steps were taken in order to appropriately
evaluate the LPAD also in terms of accuracy (see Appendix D).
For replication purposes, the Vulcan implementation is publicly available at: https://github.
com/Aifred-Health/Vulcan. All other benchmarks, as well as our DPNN implementation and
data analysis scripts, are publicly available at: https://github.com/Aifred-Health/DPNN_
Experiment.

5.2 Evaluation metrics
In many prediction tasks, the Area Under The Curve (AUC) is the central metric of choice for
evaluating a model’s performance. However, for our task, the AUC metric does not fully reflect
the quality of the output, since it is not a top-biased measure [45]. More specifically, in our setting, our prime objective is to select an optimal treatment which is most likely to provide a
desirable outcome. Therefore, errors at the top of the list of treatments, sorted by their likelihood for desired outcome (i.e., either ranking a “bad” treatment at the top of the list or ranking
a “good” treatment at the bottom of the list), are more critical than errors in the rest of the list.
Through this perspective, our evaluation is akin to that of learning to rank tasks, which require
different metrics than other prediction tasks do. Therefore, in addition to the AUC metric, we
adopt the standard Mean Reciprocal Rank (MRR) [46] commonly used in learning-to-rank
tasks.
Formally, let ~
ri be the vector of real remission probabilities for patients i across all possible
~i be the vector of predicted remission probabilities. MRR is calculated as foltreatments, and pr
lows:
1 X
!
rankp~i ðargmaxðpriÞÞ
jSj i¼0
jSj

MRRðSÞ ¼

ð10Þ

!

where S is the evaluation set and argmaxðpriÞ is the treatment with the highest remission prob!
ability for patient i, according to the model’s output. rankp~i ðargmaxðpriÞÞ is therefore the real
rank of selected treatment.
Similarly, we define the following Remission Prediction Loss (RPL) which measures the difference between the true remission probability of the selected treatment and the highest remission probability across all treatments as follows:
1 X
ðmaxð~
ri Þ
jSj i¼0
jSj

RPLðSÞ ¼
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!

where ri argmaxðpri Þ is the true remission probability of the treatment with the highest predicted
remission probability.
The MRR and RPL metrics capture different notions for measuring the discordance
between the treatment selected and the optimal one. MRR captures this notion in terms of
ranking order while RPL captures the same by effectiveness differences. Notice that for the
MRR metric—the higher the score—the better, while for the RPL metric—the lower the
score—the better.
Unfortunately, calculating the MRR and RPL can only be done in settings where some
counterfactual knowledge is available. For example, MRR can only be calculated if the data
contains the true ordering over the possible treatments for patients. While such data is available in Experiment 1 (synthetic data), it is unavailable in Experiment 2 (real-world clinical
data). Therefore, in Experiment 2, we adopt a different metric as proposed in other similar
medical treatment selection works (e.g., [32]) called Remission Rate or RR for short. The idea
behind the RR measure is to use the test set such that for each patient in it, the model is executed and the predicted optimal treatment is identified. Then, we filter out all patients in the
test set who did not receive the predicted optimal treatment. Through this process, we are left
with a subset of the original set of patients, all of whom had received the predicted optimal
treatment in practice. Based on these patients alone, the average remission rate, i.e., the portion
of remission-labeled patient-treatment pairs, is calculated and reported as the RR of the
model. Since we are using a k-fold evaluation technique, we derive a set of RR results, one for
each fold. Note that this procedure is not optimal since the RR metric is only based on a (possibly small) subset of patients. In addition, unlike the MRR and RPL metrics, the RR metric does
not reflect the quality of the ranking, which is desirable in our setting. Despite the fact that the
RR is not an optimal metric, it is a meaningful one- it represents the proportion of patients
who would reach remission if they were assigned treatments using the model, which can then
be compared to the baseline remission rate in order to determine the clincal value of the
model.

5.3 Experiment 1—Synthetic data
5.3.1 Data generation. In this study, we consider settings where patients can be assigned
one of multiple possible treatments and: 1) The patients can be divided into sub-groups that
differ in their reactions to different treatments; and 2) These sub-groups are defined in the
latent space, which is not directly observable by the model, meaning that the features that
define these clusters are not given as input to the model. As such, in order to generate appropriate synthetic data that adheres to these assumptions we perform a “reverse engineering”like process, starting with a set of randomly generated “prototypes”, around which fictitious
patients are created. We assume four possible treatment exist, and each treatment is associated
with a unique function that maps a patient to an outcome. These functions were non- linear
and generated randomly. Each patient is randomly assigned to one of four treatments and the
associated likelihood of remission. The resulting dataset consists of 10,000 patients which are
represented in the slightly noisy feature space yet are clustered around 5 prototypes in the
latent space. The parameters used for our data generation procedure were not meaningful in
the context of our task and when those were varied little difference in patterns was encountered. We describe the process in more detail in Appendix C, and the script for generating the
data is available in https://github.com/Aifred-Health/DPNN_Experiment.
5.3.2 Training. We separated the dataset into a training set and a test set using the k-fold
cross validation technique [47], in which the dataset is split into k consecutive folds and each
fold is used once for the test set while the k − 1 remaining folds are used for the training set.
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We report the results for k = 5, while similar results were obtained for other standard choices
for k. For each of the splits, we trained and tested the DPNN and each of the benchmark algorithms in the same way. We repeated this process 100 times in order to obtain a sufficiently
large results pool and subsequently obtained 100 samples of each metric for each method.
All clustering algorithms (DPNN, LPAD and Kmean) were executed assuming 5 clusters.
We obtained the hyper-parameters by an automated process that searched various combinations of parameters and found the combination that yielded the best results. We ran all models
for 100 epochs, with 10 samples in each batch and a 0.0001 learning rate. We found that our
network performed best with a single hidden layer in both the autoencoder and the classification network. Appendix A provides the fully hyper-parameter setup we used and the hyperparameter tuning process.
5.3.3 Results. For all examined metrics, the results do not distribute normally according
to the Shapiro-Wilk test [48], a standard issue when analyzing the performance of machine
learning algorithms [49]. As such, we use the Friedman’s test [50] followed by post-hoc Wilcoxon signed rank significance tests (Wilcoxon’s test for short) [51] for pairwise comparisons
with proper p-value adjustment using Bonferroni correction [52].
The Friedman’s test showed that the evaluated methods differ significantly on all examined
metrics (MRR, RPL and AUC), p � 0.01.
For the MRR metric, we found the DPNN model was significantly superior to all the benchmarks (p � 0.01) with DPNN demonstrating a median MRR of 0.451 (median absolute deviation, MAD for short = 0.004) followed by the Vulcan method (median = 0.441, MAD = 0.005),
KMNN (median = 0.444, MAD = 0.013), CFR (median = 0.444, MAD = 0.014), CBR
(median = 0.442, MAD = 0.011), and LPAD (median = 0.44, MAD = 0.006). Recall that for
MRR, the higher the better.
Similar results were encountered for the RPL metric. The DPNN model (median = 0.084,
MAD = 0.006), was significantly superior to Vulcan (median = 0.097, MAD = 0.006), CFR
(median = 0.091, MAD = 0.001), CBR (median = 0.09, MAD = 0.006), and LPAD
(median = 0.091, MAD = 0.007), while no significant difference were found when comparing
DPNN and KMNN (median = 0.084, MAD = 0.006), p � 0.01. Note that DPNN demonstrates
better performance than KMNN, yet the difference is not statistically significant. Recall that
for the RPL metric, lower numbers are preferable.
Table 3 summarizes the results and presents the performance of all methods also in specificity, sensitivity, positive predictive value (PPV) and negative predictive value (NPV) [53].
DPNN, KMNN and LPAD receive the number of clusters (or prototypes), ℓ, as input. Since
the data was originally generated from 5 prototypes, we chose to use the correct input for all
three methods. A full sensitivity analysis by ranging ℓ from 2 to 9 shows that slight changes to
Table 3. Experiment 1 (synthetic data): Median scores for each evaluated method (column) and evaluation metric (row). For all metrics ecepts RPL, the higher the better. For RPL, the lower the better. Results in bold are significantly superior to non-bold results, p � 0.01.
Method DPNN
Vulcan
CFR
CBR
KMNN
LPAD
Metric
MRR

0.451

0.441

0.444

0.442

0.444

0.44

RPL

0.084

0.097

0.091

0.09

0.084

0.091

AUC

0.751

0.777

0.754

0.755

0.739

0.732

Sensitivity

0.07

0.182

0.257

0.087

0.024

0.183

Specificity

0.986

0.964

0.914

0.808

0.98

0.824

PPV

0.502

0.488

0.622

0.366

0.471

0.375

NPV

0.333

0.344

0.319

0.314

0.327

0.329

For all metrics ecepts RPL, the higher the better. For RPL, the lower the better. Results in bold are significantly superior to non-bold results, p � 0.01.
https://doi.org/10.1371/journal.pone.0258400.t003
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this input result in little effective change for DPNN and that the correct number of clusters
could be identified using the elbow method, see Appendix F for complete details.

5.4 Experiment 2: MDD clinical data
As discussed before, in real-world clinical data our evaluation possibilities are narrower since
the data includes only the outcome of a single treatment with no practical way to obtain the
counterfactuals. Therefore, the MRR and RPL metrics cannot be evaluated on real data and are
replaced by the RR metric (see Section 5.2). Therefore in experiment 2 we report the results on
the AUC and RR metrics alone.
5.4.1 Data. The real world data consisted MDD patient level data from multiple clinical
trials: CO-MED [54], STAR� D [55], REVAMP [56], EMBARC [57] and IRL-GREY [58]. Alltogether, the dataset described 4754 patients. In these studies, patients were and randomized
to different anti-depressant treatments, and regularly reported their depressive symptoms
every few days, with common questionnaires for evaluating depression, such as The 16-Item
Quick Inventory of Depressive Symptomatology (QIDS) [59] and Hamilton Depression Rating Scale (HAM-D) [60]. Each patient was described by 26 features, including features describing the initial depressive disorders (e.g. suicidal ideation and fatigue) as reported in the
questionnaires at the beginning of the study and social-demographic features (e.g. age and
education). In addition, the data included for each patient a “treatment feature”, describing
the treatment he or she received. The “treatment feature” indicated one from 6 possible antidepressant treatment courses: escitalopram, citalopram, venlafaxine, sertraline, and the combinations of bupropion and escitalopram, and mirtazapine and venlafaxine. In addition, every
patient had a binary outcome label: remission or no-remission. The full description of the
data, including the 26 features and the pre-processing procedure are presented in Appendix B.
5.4.2 Training. Unlike Experiment 1 where the true number of prototypes was known
(chosen by us), in this experiment, we first evaluated the performance of each method by varying the value of ℓ from 2 to 9. The full sensitivity analysis results are presented in Appendix F.
We found that in both DPNN and KMNN the model performed best with 6 prototypes (ℓ = 6)
and that the LPAD method performed best with three prototypes (ℓ = 3). Therefore, in this
experiment we set ℓ = 6 for the DPNN and KMNN and ℓ = 3 for the LPAD evaluation.
5.4.3 Results. As was the case in Experiment 1, the results using both metrics (AUC and
RR) were not normally distributed using the Shapiro-Wilk normality test [48]. As such, following the same analysis procedure of Experiment 1, we use the Friedman’s test followed by posthoc Wilcoxon tests for pairwise comparisons with Bonferroni correction.
Using the Friedman’s test, we found that the methods vary significantly in both RR and
AUC scores (p � 0.01).
For the RR metric, pairwise comparisons reveal that the DPNN significantly outperforms
all other benchmarks with a median score of 0.446 (MAD = 0.039) compared to Vulcan which
demonstrated a median score of 0.413 (MAD = 0.035), CFR (median = 0.418, MAD = 0.045),
CBR (median = 0.415, MAD = 0.025), KMNN (median = 0.412, MAD = 0.032) and LPAD
(median = 0.411, MAD = 0.016), p � 0.01. Interestingly, the KMNN significantly outperformed all other benchmarks (other than DPNN), p � 0.01. It is important to note that the
general remission rate, i.e. the portion of remission-labeled patients in the entire dataset, is
only 0.355. Namely, all evaluated methods have demonstrated an expected added benefit compared to a random treatment selection procedure. Note that the RR metric is based on a varying number of samples (see Section 5.2). Nonetheless, the above results are found to be
statistically significant. Table 4 summarizes the results. As mentioned above (Section 5.2), the
RR metric is based only on a subset of patients from the test set (the patients who received the
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Table 4. Experiment 2 (clinical data): Median scores for each evaluated method (column) and evaluation metric (row). For both metrics, the higher the better. Results
in bold are significantly superior to non-bold results, p � 0.01.
Method DPNN
Vulcan
CFR
CBR
KMNN
LPAD
Metric
RR

0.446

0.413

0.418

0.415

0.412

0.411

AUC

0.64

0.65

0.626

0.58

0.595

0.608
0.017

Sensitivity

0.075

0.175

0.471

0.25

0.032

Specificity

0.965

0.926

0.817

0.811

0.987

0.985

PPV

0.522

0.509

0.611

0.385

0.492

0.343

NPV

0.36

0.37

0.306

0.365

0.357

0.355

For both metrics, the higher the better. Results in bold are significantly superior to non-bold results, p � 0.01.
https://doi.org/10.1371/journal.pone.0258400.t004

optimal treatment within the test set). In all models, this group of users were in average
between 30% and 40% of the test set (between 287 and 383 patients).
As was the case in Experiment 1, Vulcan was significantly superior to all other methods in
terms of AUC achieving a median score of 0.65 (MAD = 0.001) compared to DPNN
(median = 0.64, MAD = 0.011), CBR (median = 0.58, MAD = 0.013), KMNN (median = 0.595,
MAD = 0.012), CFR (median = 0.626, MAD = 0.01), LPAD (median = 0.608, MAD = 0.011),
p � 0.01. Nonetheless, DPNN significantly outperforms CFR, KMNN, CBR and LPAD methods, p � 0.01.
Table 4 summarizes the main results presented above. In addition, the table presents the
performance of all methods in specificity, sensitivity, PPV and NPV measures.

6 Discussion
The experimental results presented in Section 5 demonstrate the advantages and limitations of
our proposed DPNN approach. In both experimental setups, we see that the DPNN favorably
compares with several state-of-the-art methods for treatment selection in terms of its low discordance with the unknown optimal treatment selection policy at a minimal expense in prediction accuracy. Specifically, for the MRR, RPL and RR metrics, we see that the DPNN
significantly outperforms all benchmark methods. On the other hand, in order to achieve this
advantage, as the DPNN is shown to have slight reduction in its performance in terms of
AUC. From a practical perspective, it is claimed that “a prediction model is only as good as its
resulting agent’s performance” [61]. Adopting this viewpoint means that, in several decisionmaking environments, the DPNN’s tradeoff of AUC performance for MRR, RPL and RR performance is worthwhile. This is because the purpose of the model is to increase the number of
patients reaching remission; a significant increase in this metric has more clinical value than
less than a percent difference in an accuracy metric. As such, we expect that the DPNN
approach will prove more valuable as a clinical decision support technology compared to the
evaluated state-of-the-art methods.
When presenting a new approach such as the DPNN, it is worthwhile discussing its limitations. First, as discussed above, DPNN has a small decrease in AUC performance to improve
other, arguably more important, metrics. In environments where AUC is the prominent metric for evaluation, this may result in other methods (such as Vulcan) being preferred. We
believe that in many medical decision-making environments, and specifically in MDD treatment selection, DPNN advantages supersede its limitations.
Second, DPNN requires the number of prototypes to be defined before execution. This is a
standard limitation to most clustering-based algorithms and can be largely mitigated by adopting one of the many clustering analysis techniques commonly used for determining the
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optimal number of clusters to use in a dataset [62]. In addition, as shown in Appendix F,
DPNN is not very sensitive to the number of clusters in the data considered, which requires
further investigation in order to determine the best way to interpret the clinical or biological
meaning of the resulting clusters. Lastly, DPNN is built on several rather restrictive assumptions as outlined in Section 4. Specifically, it is unlikely that the assumption that samples (i.e.,
patients) can be divided into sub-groups which significantly differ in their reactions to different treatments will hold in all decision-making domains. While this theoretically limits the
applicability of the DPNN approach, it appears that such settings are prominent, especially in
the mental healthcare domain. Given the abundance of mental conditions, their prevalence in
the general public and the great costs associated with them, DPNN can prove useful to a variety
of high-impact treatment selection environments.
The architecture of our network, and specifically the prototypes learned by the network,
can potentially increase the interpretability of the network’s results, which is essential in an
automated depression treatment selection system. Recent work demonstrates interpretability
can drive physicians trust in an automated treatment selection system, which in turn can influence their use of the system’s results [63]. This makes model interpretability a prime target for
improving the physician-AI interaction. Therefore, in future work we plan to investigate how
to explain the DPNN results to clinicians and how the network’s results are perceived by both
the clinicians and the patients.

7 Conclusions
In this article, we propose and evaluate a novel deep learning-based approach, DPNN, that
simultaneously identifies sub-groups of patients as well as predicts personalized treatment outcomes. Our approach is shown to strike a delicate balance between the fully personalized paradigm (which ignores any possible clustering of patients) and the sub-grouping paradigm
(which ignores individual differences within the groups) and favorably compares to existing
benchmarks using synthetic and real-world clinical data.
Focusing on the important challenge of personalizing depression treatment, our approach
demonstrates significant advantages over existing state-of-the-art methods. These advantages
can potentially be translated into a significant reduction of the burden of depression in both
the patient level and in the population-level and lead to a superior level of care.
As mentioned above, the actual remission rate in our dataset was 35.5%. Therefore, the
DPNN method produced an 8% absolute and 23% relative improvement over random treatment allocation. In current practice, patients can be prescribed any of a number of treatments,
with treatments considered equally effective at the population level, approximating a random
assignment at scale. Therefore, these results are potentially clinically significant- given the
large number of patients with MDD, a 23% improvement over current practice could mean
potentially a very large number of patients reaching remission earlier and without needing to
try multiple treatments.
We intend to extend this work in two directions: First we are currently preparing our system to be tested in a live clinical trail. This trial may shed new light on additional factors relating to the treatment selection process. For example, we expect that the interpretability of the
model will be identified as an issue for further research (see [64] for a recent overview). We
believe that the DPNN approach can enable physicians to gain insights through the learned
prototypes and their “resemblance” to each individual patient. We plan to investigate this
human-computer interaction issue in the future. Second, in this work, we primarily focused
on the performance of our models in terms of selected treatment efficacy. As such, we intend to
extend our analysis of the prototypes outputted by associating clinical meanings to each
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Table 5. Hyper-parameters of the DPNN model in both experiments.
hyper-parameter

meaning

value in experiment 1

value in experiment 2

ℓ

number of prototypes

6

5

hidden-layers in e

number of hidden-layers and nodes in the auto-encoder

12 nodes, single layer

18 nodes, single layer

hidden-layers in h

number of hidden-layers and nodes in the classification network

12 nodes, single layer

11 nodes, single layer
0.0001

learning-rate

controls how quickly the model is adapted during training

0.0001

epochs

number of epochs in training

75

90

batch size

number of training examples utilized in one iteration

10

10

λ1

auto-encoder loss (L2) weight (Eq 9)

0.01

0.01

λ2

auto-encoder prototype variance loss (L3) weight (Eq 9)

0.05

0.06

α

balance of the prototype variance loss (Eq 6)

0.85

0.95

https://doi.org/10.1371/journal.pone.0258400.t005

prototype. This additional analysis and interpretation is challenging yet it can prove very beneficial from a clinical perspective. Last, we plan to experiment with additional decision-making
domains, both medical and non-medical, to better understand the advantages and limitations
of our approach.

8 Appendices
A Model training parameters
The DPNN method includes several hyper-parameters that can be configured and effect the
model’s performance. In this appendix, we present the values of the hyper-parameters used in
both our experiments. The full list of hyperparameters are presented below in Table 5.
In both experiments, we set the hyper-parameters λ1 to 0.01 λ2 to 0.05, α to 0.85 and the
learning rate to 0.0001. These parameters were found to be most useful using a simple gridsearch.
Regarding the inner layers of the model, we found that the model performed best, in both
experiments, with one inner layer in the auto-encoder component (one inner layer in the
encoder and a symmetrical layer in the decoder). In the first experiment, the layer consisted 14
nodes and in the second experiment 18 nodes.In addition, in both experiments the classifier
layers components included one hidden layer, In experiment 1, the layer consisted 16 nodes
and in experiment 2 we used 11 nodes.
We obtained the hyper-parameters by an automated process that searched various combinations of parameters and found the combination that yielded the best results.
Test size influence. In our experiments we used a 5-fold validation, therefor the test size
was 20% of the original dataset. In order to investigate the influence of the test size on the performance of the DPNN model with the MDD data, we tried splitting the data by 4 other possible train-test ratios: 5% (test ratio), 10%, 25%, 50%. For each of these ratios, we ran the model
10 times and measured the median RR measure and the AUC. In Table 6, we present the
Table 6. Train-test ratio influence on the performance of the DPNN model with the MDD data, medians results.
test-train ratio

RR

5: 95

AUC
0.375

0.645

10: 90

0.41

0.635

20: 80

0.446

0.64

25: 75

0.411

0.621

50: 50

0.433

0.631

https://doi.org/10.1371/journal.pone.0258400.t006
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median result. The results in the third row, for the 20:80 ratio, are the results in we obtained
with the 5-fold cross validation, which we reported in our paper. This ratio gave the best result
in RR measure, which is our prime objective.

B The MDD data description
The real world data consists of MDD patient-level data from several major clinical trials:
CO-MED [54], STAR� D [55], REVAMP [56], EMBARC [57] and IRL-GREY [58]. Combining
studies was necessary in order to include enough different treatments to produce a model of
potential clinical value (as a model which simply assists in selecting between one treatment or
another is not likely to be of clinical use when over a dozen treatments and treatment combinations can be selected from). CO-MED enrolled outpatients with MDD who were randomized to three anti-depressant treatment arms: escitalopram and placebo, bupropion and
escitalopram, or mirtazapine and venlafaxine. The purpose of the trial was to assess whether
combination treatment was superior to monotherapy, but similar remission rates were
observed in each arm. STAR� D is the largest pragmatic trial of depression treatment ever conducted to date and followed patients through multiple courses of treatment; in our dataset we
look at the first stage of treatment of the four levels of the study (which is the level analyzed in
this study), all patients received citalopram, and the remission rate was 33%. we used the first
stage because we were interested in predicting response to an initial monotherapy trial, and
also because sample size decreased significantly in later stages of the study. As it was a pragmatic study, aside from requiring that patients have at least moderate severity major depression, there were few strict exclusion criteria (other than medical instability or substance abuse
disorders that requiring detoxification, eating disorders, or obsessive compulsive disorders)
making the study fairly representative of a real clinical sample (n = 2876). REVAMP was a
study comparing a medication with two different psychotherapies added to the medication; we
analyzed the medication only group, which included patients on escitalopram, bupropion,
venlafaxine or mirtazapine (however due to small sample size we were unable to include the
patients on mirtazapine for this analysis). Patients needed to have chronic depression, and
were not allowed to have psychotic disorders, bipolar disorder, post traumatic stress disorder,
obsessive compulsive disorder, eating disorders, substance abuse or personality disorders.
EMBARC was a study focused on finding biomarkers of depression treatment response; we
use the sertraline and bupropion arms of the study as these treatments as monotherapy were
not available in other data sets we had access to. Finally, IRL-GREY was a study of older adults
with depression; we use the data from the first stage of the study, where all patients recieved
venlafaxine monotherapy.
All in all, we had seven different treatments available for the model to learn to predict
remission rates for: bupropion, escitalopram, citalopram, venlafaxine, sertraline, and the combinations of bupropion and escitalopram, and mirtazapine and venlafaxine. However, in this
study we excluded the group of patients that received bupropion only since it was very small in
comparison to the other groups (65 patients). These are all first-line or combinations of firstline treatments and are commonly used in clinical practice [65]; while they are essentially
equally effective at the population level when looking at the data from each of these studies,
clinically they are used differently and in usual practice are thought to help different kinds of
patients in a differential manner [66]. We did not use data from placebo arms from any of the
studies; given these are all known to be effective treatments, comparison to placebo to prove
efficacy was not necessary and would not have provided useful information in predicting differential treatment response, though in future work we plan to assess prediction of differential
response to placebo, as in [67]. When determining patient remission status, we took an “intent
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to treat” approach, using all patients (even those who dropped out before study end as long as
they had been in the study for a minimum of two weeks, as prior to two weeks there is not
likely to be any effect of treatment) and ascertaining remission at the last possible measurement in order to capture the state of the patient as they were leaving the study (as a parallel to
the last point at which they would be leaving treatment in a real clinical setting). While this
results in a remission rate that would be lower than that observed if one were to look only at
remission rates at the end of the study and therefore to greater lack of balance between the
remission and non-remission categories- it also provides a dataset closer to true clinical reality
and which matches the remission rates reported in the included studies. The sample was
37.6% female. The sample overall included patients with similar remission rates, a high rate of
chronic or recurrent depression, and generally with patients with psychiatric comorbidities
permitted to enroll in most studies. All the datasets together included 4754 patients, with an
overall 35.5 percent remission rate. These studies were ideal for our analysis because they
included similar eligibility criteria and outcome measures and generally allowed clinicians to
tailor patient dose to patient need and tolerance, as in real practice. They were all carried out
as investigator-initiated studies of well-known treatments as well, and were more focused on
comparative efficacy than on getting a new treatment approved.
The data initially included 213 features, and the model performed poorly on the the raw
data. Therefore, we first employed the following methods for feature reduction in order to
improve the various models’ results:
1. Feature importance thresholding via randomized Lasso: This procedure randomly shuffled
the samples and selects the set of features most closely linked to the label we were trying to
predict (i.e. remission).
2. Recursive feature elimination with cross validation (RFECV): This method trains a model
with subsets of the original feature list and detects the features with the most value for the
performance of the model.
We were able to identify a list of 26 optimal parameters (not including the target value and
treatment feature) for our feature selection by iteratively running the features with our models
and assessing the prediction metrics. These methods were implemented from the Python package Sci-kit Learn.
In addition, at a later step during model development we removed one of the seven original
treatment courses, bupropion, since it only included 63 instances in the data. We are currently
working to secure more data on patients using this treatment, so future iterations of the model
can include this and potentially other treatments as well.
Features list. Here we list the final features used in our model. all features are categorical
and were reported by various questionnaires.
1. From HAM-D questionnaire: Poor appetite or overeating.
2. From HAM-D questionnaire: Impact of your family and friends.
3. From HAM-D questionnaire: Early morning insomnia.
4. From HAM-D questionnaire: Energy/ fatigability.
5. From HAM-D questionnaire: Pleasure/enjoyment.
6. From HAM-D questionnaire: Reactivity of mood.
7. From HAM-D questionnaire: Suicidal ideation.
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8. From HAM-D questionnaire: Sympathetic arousal.
9. From HAM-D questionnaire: Outlook towards future.
10. From HAM-D questionnaire: Fatigue.
11. From HAM-D questionnaire: Has private insurance.
12. QIDS total score (the sum of all symptom values in the QIDS questionnaire).
13. Number of relatives living with patient.
14. From QIDS questionnaire: Appetite (increased).
15. From QIDS questionnaire: Concentration/decision making.
16. From QIDS questionnaire: Energy/fatigability.
17. From QIDS questionnaire: Involvement.
18. From QIDS questionnaire: Mood (sadness).
19. From QIDS questionnaire: Mid-nocturnal insomnia.
20. From QIDS questionnaire: Suicidal ideation.
21. Climbing several flights of stairs.
22. Currently employed partial or full time.
23. 16 or more years of education.
24. Number of friends living with patient.
25. One to four number of relatives living with patient.
26. One to five number of persons in household.

C Synthetic data generation
In this appendix we describe in detail the process of data generation for the synthetic data we
used in Experiment 1 (Section 5.3). First, we randomly created a set of 5 prototypes (ℓ = 5),
where each prototype is represented as a 10 feature vector (q = 10), each of which is sampled
from a normal distribution with a mean of 0 and standard deviation of 10. For each prototype,
we generated a set of 2,000 fictitious patients in the latent-space according to the same normal
distribution around the prototypes. Each patient was randomly assigned to one of four treatments (k = 4).
Each of the four treatments was associated with a randomly chosen non-linear remission
function that maps patients’ latent features to a probability of remission. The remission function determines the remission probability using two linear matrix multiplications with a RELU
activation function in between. All the values of the matrices were randomly generated from a
standard normal distribution. The first matrix’s size was 10 × 5 and the second matrix 5 × 2.
As before, slight variations to these parameters and other choices of non-trivial remission
functions have demonstrated similar results. The outcome for each patient-treatment pair,
namely remission or non-remission, was chosen using a softmax operator over the results of
the above calculation.
To complete the process, each generated patient was “decoded” into 16 observable (nonlatent) features using a decoder function. The decoder function uses a matrix multiplication
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where the matrix’s size was 10 × 16. All the values of the matrix were randomly generated from
a standard normal distribution. In addition, in order to avoid over-simplicity, the decoder
function added 4 irrelevant features to the observed space. These features that were randomly
generated from the standard normal distribution. altogether, each patient was now represented
by 20 features (d = 20).
Overall, the above process produced a synthetic dataset of 10,000 patients represented in
the non-latent space, each associated with one random treatment and an outcome. The script
we used for this process was implemented in python and is publicly available at: https://github.
com/Aifred-Health/DPNN_Experiment/tree/master/Experiment/Synthetic_Data_
Experiment.

D LPAD
In our experiments we compared our model to LPAD: a sub-grouping method for treatment
of depression, based on Latent Profile Analysis. We mentioned above (Section 5) that this
method we first divided our dataset into train and test sets (80%-20% split), and executed the
original LPAD procedure on the training set. Then, using the test set, we first classified each
patient to the nearest cluster. We then use the data from the patients allocated to each cluster
in order to estimate the remission likelihood for that cluster through a standard maximum
likelihood estimation. This way, we were able to obtain the optimal treatment for each patient,
based on his associated cluster. We used this procedure in order to calculate all the metrics
described in Section 5.2.

E CFRNet adjustment
CFRnet was originally designed for data including two groups of treatments, however the
authors mention that the method can be trivially extended to multiple treatments, by estimating the outcome for each pair of treatments and aggregating the results [31]. In our evaluation
we followed their suggestion in both experiments as follows: For each sample, we predicted the
outcomes of each possible per of interventions (treatments), and than we averaged the results
for each intervention. Consequently, we obtained for each sample a predicted outcome for
each possible intervention and specifically for the intervention he or she actually received, and
we used these results for calculating the various metrics.

F Sensitivity analysis
In our experiments we evaluated three methods that involve prototyping or clustering: DPNN,
KMNN and LPAD. Before comparing the models’ performance, we first analyzed the effect of
Table 7. Sensitivity analysis- synthetic data. Performance by Number of Clusters.
DPNN
AUC

kmean
MRR

RPL

AUC

LPAD
MRR

RPL

AUC

MRR

RPL

2

0.73

0.42

0.1

0.71

0.44

0.09

0.74

0.44

0.08

3

0.74

0.44

0.1

0.71

0.44

0.11

0.74

0.44

0.08

4

0.74

0.44

0.1

0.76

0.44

0.08

0.74

0.44

0.09

5

0.75

0.45

0.09

0.74

0.44

0.09

0.73

0.44

0.09

6

0.75

0.45

0.09

0.76

0.42

0.08

0.74

0.44

0.09

7

0.73

0.44

0.1

0.77

0.44

0.09

0.74

0.44

0.09

8

0.77

0.43

0.08

0.77

0.41

0.08

0.74

0.44

0.1

9

0.75

0.44

0.09

0.76

0.46

0.08

0.73

0.43

0.1

https://doi.org/10.1371/journal.pone.0258400.t007
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Table 8. Sensitivity analysis- MDD data. Performance by Number of Clusters.
DPNN
AUC

Kmean
RR

AUC

LPAD
RR

AUC

RR

2

0.61

0.42

0.59

0.41

0.6

0.42

3

0.6

0.42

0.6

0.38

0.61

0.42

4

0.61

0.43

0.59

0.42

0.61

0.39

5

0.64

0.43

0.59

0.42

0.61

0.4

6

0.64

0.43

0.59

0.42

0.62

0.39

7

0.62

0.42

0.63

0.38

0.62

0.39

8

0.63

0.43

0.63

0.36

0.61

0.4

9

0.64

0.42

0.63

0.39

0.62

0.4

https://doi.org/10.1371/journal.pone.0258400.t008

the number of prototypes (or clusters) on the performance of the models. All three methods
were executed with the number of prototypes ranging from 2 to 9. For each number of prototypes, we ran the models 5 times and obtained the average value of all metrics. We found that,
in Experiment 2, for the RR metric in the MDD data, the model performed best with 6 prototypes, for both the DPNN and KMNN models. The results for both experiments, are presented
in Tables 7 and 8.
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